NYU Langone


NYU Langone Among First to Treat COVID-19 Patients with Novel Antibody Arising out of UBC Spinoff Platform & Rapid Lilly Drug Development

NYU Grossman School of Medicine recently began treating patients in a clinical trial to determine whether an antibody therapy known as LY-CoV555 can safely reduce COVID-19 severity. Sponsored by Eli Lilly and Company, this experimental treatment consists of...

Pin It on Pinterest